Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GS 4774

Next Previous
Drug Profile

GS 4774

Alternative Names: GI 13020; GS-4774; Inactivated recombinant Saccharomyces cerevisiae expressing Hepatitis B virus X, surface and core antigens (GI-13020); Tarmogen T cell immunity stimulator

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlobeImmune
  • Developer Gilead Sciences
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 15 Jun 2018 GS 4774 is still in phase II trials for Hepatitis B (GlobeImmune pipeline, June 2018)
  • 30 May 2018 Gilead Sciences completes a phase II trial in Hepatitis B (Combination therapy) in USA, Canada, New Zealand, Romania, South Korea and Italy (SC) (NCT02174276)
  • 19 Apr 2017 Updated efficacy and immunological data from a phase II trial in Hepatitis B presented at the International Liver Congress (ILC-2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top